BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260716T190000
DTEND;TZID=Africa/Nairobi:20260716T203000
DTSTAMP:20260820T223526Z
CREATED:20260716T130048Z
LAST-MODIFIED:20260820T223526Z
UID:41816-1784228400-1784233800@kesho-kenya.org
SUMMARY:Advancing Cardio-Oncology in East Africa
DESCRIPTION:Advancing Cardio-Oncology in East Africa\nFrom Evidence to Everyday Practice \n\nDate: Thursday\, 16th July 2026\nTime: 7:00 PM – 8:30 PM EAT\n\nSpeakers \n\nDr. Anne Mwirigi; \n\nConsultant Haematologist & Assistant Professor | Aga Khan University Hospital\, Nairobi \n\nDr. Kieran Mwazo\n\nConsultant Cardiologist | Head of the Cardiology Division | Coast General Teaching and Referral Hospital\, Mombasa \n\nDr. Joseph Abuodha\n\nConsultant Medical Oncologist | Department of Haematology and Oncology | Aga Khan University Hospital\, Nairobi \nModerator \n\nProf. Arjun Ghosh\n\nConsultant Cardiologist | Barts Heart Centre\, St. Bartholomew’s Hospital | London & University College London Hospital \nSummary\nThis joint KESHO and Kenya Cardiac Society session explored how cardiovascular care can be integrated into cancer treatment from baseline assessment through active therapy and long-term survivorship. \nA central theme was that advances in cancer treatment have created a growing population of survivors while also expanding the range of potential cardiovascular effects. Dr. Anne Mwirigi set the scene by tracing the evolution of cancer therapy and highlighting how conventional chemotherapy\, targeted treatments and newer agents may affect the heart and vascular system in different ways. \nDr. Kieran Mwazo brought the discussion into the East African setting\, emphasising that cancer and cardiovascular disease share several risk factors and frequently coexist. Baseline assessment\, optimisation of existing cardiovascular disease and structured surveillance can help identify patients who need closer monitoring. ECG\, echocardiography\, global longitudinal strain\, cardiac biomarkers and advanced imaging were discussed as tools for detecting treatment-related injury before it becomes clinically advanced. \nThrough clinical cases\, Dr. Joseph Abuodha illustrated the complexity of decisions when cardiac toxicity develops during potentially life-prolonging cancer treatment. Bradyarrhythmias\, changes in cardiac function and suspected treatment-related myocardial injury highlighted the need to consider both oncological benefit and cardiovascular risk rather than automatically prioritising one condition over the other. Shared decision-making and close collaboration between specialties were repeatedly emphasised. \nThe session also looked beyond individual cases to the systems needed for cardio-oncology in Kenya and the region\, including integrated referral pathways\, locally adapted protocols\, workforce development and stronger data collection. Across the session\, a consistent message emerged: cardio-oncology is about protecting cardiovascular health without unnecessarily compromising effective cancer treatment. \nKey Takeaways\n\nCardiovascular assessment should begin before potentially cardiotoxic cancer treatment is started.\nModern cancer therapies can produce a broad range of cardiovascular effects beyond heart failure alone.\nRisk-adapted surveillance using ECG\, echocardiography\, strain and biomarkers can support earlier detection of toxicity.\nTreatment decisions should balance oncological benefit with cardiovascular risk through multidisciplinary and shared decision-making.\nEast Africa needs stronger cardio-oncology pathways\, training\, locally relevant protocols and regional data.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/advancing-cardio-oncology-in-east-africa/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-16-at-12.28.17-PM-e1784206835252.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260723T193000
DTEND;TZID=Africa/Nairobi:20260723T203000
DTSTAMP:20260820T222912Z
CREATED:20260721T125010Z
LAST-MODIFIED:20260820T222912Z
UID:41828-1784835000-1784838600@kesho-kenya.org
SUMMARY:Management of Treatment-Induced Neurotoxicity
DESCRIPTION:Management of Treatment-Induced Neurotoxicity session \n23rd July 2026\, 7–8:30 PM EAT\, \nFeaturing Dr. Herman Ekea\, Dr. Karishma Sharma\, and Dr. Juzar Hooker \n    	\n        Click to Register
URL:https://kesho-kenya.org/event/management-of-treatment-induced-neurotoxicity/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-20-at-12.54.09-PM-4-e1784644283295.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260730T193000
DTEND;TZID=Africa/Nairobi:20260730T203000
DTSTAMP:20260820T222730Z
CREATED:20260728T131820Z
LAST-MODIFIED:20260820T222730Z
UID:41839-1785439800-1785443400@kesho-kenya.org
SUMMARY:Implementing Precision Oncology in LMICs
DESCRIPTION:Implementing Precision Oncology in LMICs:\nFrom Diagnosis to Clinical Decision-Making \nDate: 30th July 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker\nProf. Shahin Sayed\nAssociate Professor & Consultant\, Anatomical Pathology and Cytology\, Department of Pathology\, Medical College\, Aga Khan University; Chair & Laboratory Director. Pathology\, AKUH\, N\nThe Diagnostic Foundations of Precision Oncology: Pathology\, Biomarkers and Molecular Testing \nSpeaker\nProf. Chite Asirwa\nMedical Oncologist & Hematologist; CEO\, International Cancer Institute\nPrecision Oncology in LMICs: Current Landscape\, Clinical Application and the Road Ahead \nModerator\nProf. Nicholas Abinya\nConsultant Medical Oncologist\, Nairobi Hospital Cancer Centre \nSummary\nThis session examined what meaningful precision oncology looks like in low- and middle-income countries\, connecting clinical decision-making with pathology\, molecular diagnostics\, patient factors\, health-system capacity and access to treatment. \nA central theme was that precision oncology is broader than genomic sequencing. Prof. Chite Asirwa described it as the integration of clinical\, pathological\, molecular\, environmental and patient-specific information across diagnosis\, prognosis\, treatment selection and monitoring. Used well\, this approach can reduce ineffective empirical treatment\, limit unnecessary toxicity and direct limited resources towards interventions most likely to benefit the patient. \nProf. Shahin Sayed focused on the diagnostic foundations that make precision care possible. High-quality tissue\, correct fixation and handling\, validated assays\, quality assurance and clinically useful reporting all determine whether a molecular result can be trusted. The discussion reinforced that advanced testing cannot compensate for weak foundational pathology\, and that essential immunohistochemistry and biomarker testing remain an important starting point for many settings. \nThe session also addressed Africa’s underrepresentation in genomic datasets and the challenge of interpreting variants when locally relevant reference data are limited. Molecular results need clinical context and\, where possible\, multidisciplinary interpretation. Liquid biopsy and circulating tumour DNA were discussed as promising tools for selected applications\, but standardisation\, quality control and careful use remain important\, particularly when considering screening. \nImplementation was therefore framed as a phased health-system journey rather than a technology purchase. Strong pathology services\, reliable essential biomarkers\, regional molecular capacity\, better patient navigation\, financing and locally generated data must develop together. Across the session\, a consistent message emerged: precision oncology has greatest value when a reliable test leads to a clinically meaningful decision and an accessible treatment pathway. \nKey Takeaways\n\nPrecision oncology integrates clinical\, pathological\, molecular and patient-specific information rather than genomics alone.\nAccurate pathology\, specimen quality and laboratory quality assurance are foundational to every precision treatment decision.\nEssential biomarkers and immunohistochemistry should be strengthened before indiscriminate expansion into complex testing.\nAfrican genomic data and multidisciplinary interpretation are needed to improve the relevance of molecular results.\nTesting has limited value when results cannot be linked to accessible treatment\, making financing and patient navigation part of precision care.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/implementing-precision-oncology-in-lmics/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-28-at-12.07.44-PM-3-e1785245724838.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260806T193000
DTEND;TZID=Africa/Nairobi:20260806T203000
DTSTAMP:20260820T224450Z
CREATED:20260820T224041Z
LAST-MODIFIED:20260820T224450Z
UID:41901-1786044600-1786048200@kesho-kenya.org
SUMMARY:Ovarian Cancer in Focus
DESCRIPTION:Ovarian Cancer in Focus: Innovation\, Care and Evolving Care\n\nModerator: Dr. Amina K. Habib\nSpeaker: Dr. Chris Gallagher\nDate: 6 August 2026\n\nSummary\nThis session examined recent developments in epithelial ovarian cancer\, from the continuing challenge of earlier diagnosis to surgical decision-making\, molecular stratification\, maintenance therapy and emerging options for recurrent and platinum-resistant disease. \nA central theme was the move towards increasingly biomarker-informed care. Dr. Chris Gallagher highlighted how BRCA1/2 mutations and homologous recombination deficiency are shaping treatment selection\, particularly PARP inhibitor maintenance after response to platinum-based chemotherapy. The discussion reinforced that these therapies offer the greatest value when matched to tumour biology rather than applied broadly. \nThe session also explored the challenge of finding ovarian cancer earlier. Emerging approaches using circulating DNA fragments may improve future detection\, but the evidence remains preliminary and requires wider validation. Surgical treatment was similarly framed around careful patient selection: the choice between upfront cytoreductive surgery and neoadjuvant chemotherapy should reflect disease extent\, patient fitness and the likelihood of achieving complete resection. \nFor recurrent and difficult-to-treat disease\, the discussion highlighted newer approaches including folate receptor alpha-targeted antibody-drug conjugates in platinum-resistant ovarian cancer and molecularly targeted strategies for low-grade serous disease. These developments are expanding treatment possibilities\, although the role of immunotherapy remains less clearly established. \nThe discussion brought these advances into the African context\, where access to BRCA and HRD testing\, targeted therapies and newer medicines remains uneven. Molecular testing is most meaningful when it can inform an accessible treatment pathway. In recurrent disease especially\, expected benefit must be weighed against toxicity\, quality of life\, patient fitness and financial burden. \nAcross the session\, a consistent message emerged: ovarian cancer care is becoming increasingly defined by tumour biology\, but improved outcomes still depend on appropriate surgery\, access to molecular testing\, careful patient selection and treatment pathways that reflect both evidence and real-world access. \nKey Takeaways\n\nEarlier detection remains a major unmet need\, with emerging circulating DNA approaches still requiring further validation.\nBRCA and homologous recombination status are increasingly important in guiding treatment selection.\nSurgical sequencing should be individualised\, with complete cytoreduction remaining an important treatment objective.\nPARP inhibitors and newer targeted therapies are expanding options for selected patients\, including those with recurrent or platinum-resistant disease.\nIn African settings\, clinical benefit\, treatment access\, affordability and quality of life must remain central to decision-making.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/ovarian-cancer-in-focus/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/Ovarian-Cancer-in-Focus-e1787265870600.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260813T193000
DTEND;TZID=Africa/Nairobi:20260813T203000
DTSTAMP:20260811T142645Z
CREATED:20260811T142028Z
LAST-MODIFIED:20260811T142645Z
UID:41876-1786649400-1786653000@kesho-kenya.org
SUMMARY:From Digital Diagnosis to Connected Cancer Care
DESCRIPTION:“From Digital Diagnosis to Connected Cancer Care” \nCPD ACCREDITED \nDate: 13th August 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker: Dr. Arvind Rao\nProfessor\, Department of Computational Medicine and Bioinformatics\, University of Michigan\nTalk: “From Digital Diagnosis to AI-Powered Cancer Care: Governance\, LLMs\, and the Connected Future” \nSpeaker: Dr. Joshua Kibera\nAnatomical Pathologist\, CEO/Founder – The Pathology Network\nTalk: “Beyond the Algorithm: Building the Digital Diagnostic Infrastructure for AI-Enabled Precision Cancer Care” \nModerator: Dr. Anne Korir\nSenior Research Scientist\, Kenya Medical Research Institute (KEMRI) \n    	\n        Click to Register
URL:https://kesho-kenya.org/event/from-digital-diagnosis-to-connected-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/WhatsApp-Image-2026-08-11-at-10.35.44-AM-e1786457992618.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260903T190000
DTEND;TZID=Africa/Nairobi:20260903T203000
DTSTAMP:20260924T170503Z
CREATED:20260902T225823Z
LAST-MODIFIED:20260924T170503Z
UID:41909-1788462000-1788467400@kesho-kenya.org
SUMMARY:Childhood Cancer Diagnosis
DESCRIPTION:EVERY CONTACT COUNTS: STRENGTHENING MULTIDISCIPLINARY PATHWAYS TO CHILDHOOD CANCER DIAGNOSIS \n\nModerator: Dr Brian Nderu\nSpeaker: Dr Robert Kimutai\nDate: 3 September 2026\n\nThis session focused on diagnostic delay in childhood cancer as a systems and pathway challenge rather than simply a problem of missed symptoms. \nDr Robert Kimutai discussed the different points at which delays can occur\, including delay in seeking care\, reaching appropriate services and receiving the right diagnosis and referral. He emphasized the importance of recognising persistent\, progressive or unexplained symptoms and strengthening the response at the first point of contact. \nA major theme was the need for coordinated referral pathways with clear clinical ownership. Effective childhood cancer pathways depend on communication between primary care\, referral facilities and specialist services\, with closed-loop referral systems that reduce the risk of children being lost between levels of care. \nThe discussion also broadened the concept of multidisciplinary care beyond specialist teams. Frontline clinicians\, laboratory teams\, nurses\, referral coordinators and other health workers all have a role in recognising warning signs and moving children efficiently through the diagnostic pathway. \nThe session highlighted the importance of strengthening peripheral diagnostic capacity\, particularly basic laboratory services\, while improving referral processes for children who require specialist investigation and care. \nAcross the discussion\, the central message was clear: earlier diagnosis depends not only on awareness\, but on health systems that can recognise\, refer\, investigate and follow up children consistently. \nKey Takeaways \n\nChildhood cancer diagnostic delay is often a pathway problem\, not only a recognition problem.\nPersistent\, progressive or unexplained symptoms should prompt further assessment.\nClear referral ownership and closed-loop communication can reduce delays.\nMultidisciplinary childhood cancer pathways begin at the first point of contact.\nStrengthening peripheral diagnostic capacity and measuring referral performance are important for improving early diagnosis.
URL:https://kesho-kenya.org/event/childhood-cancer-diagnosis/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/09/WhatsApp-Image-2026-09-01-at-1.23.22-PM-e1788389837394.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260909T190000
DTEND;TZID=Africa/Nairobi:20260909T203000
DTSTAMP:20260924T170645Z
CREATED:20260909T140536Z
LAST-MODIFIED:20260924T170645Z
UID:41917-1788980400-1788985800@kesho-kenya.org
SUMMARY:Advancing Hodgkin Lymphoma Care
DESCRIPTION:ADVANCING HODGKIN LYMPHOMA CARE: INCORPORATING NOVEL THERAPIES INTO CLINICAL CARE \n\nModerator: Dr Peter Oyiro\nSpeakers: Dr Anne Mwirigi\, Prof Ranjana Advani\nDate: 10 September 2026\n\nThis session examined how Hodgkin lymphoma care is evolving as PET-adapted strategies and novel therapies become increasingly integrated into clinical practice\, while keeping cure\, toxicity and access in balance. \nDr Anne Mwirigi used clinical cases to highlight two practical challenges: treatment failure can still occur despite a negative interim PET\, and tissue confirmation remains essential when the clinical course changes. The discussion reinforced the need to pursue an adequate biopsy rather than rely on presumptive diagnoses\, particularly where lymphoma may be mistaken for conditions such as tuberculosis. \nProf Ranjana Advani reviewed contemporary treatment across early and advanced-stage disease. She discussed how more precise radiotherapy has reduced exposure to normal tissues\, while PET-adapted approaches continue to refine the balance between cure and long-term toxicity. In early-stage disease\, established combined-modality treatment remains important\, as current evidence does not yet support routinely replacing radiotherapy with novel agents. \nThe session also explored the expanding role of brentuximab vedotin and checkpoint inhibitors such as nivolumab and pembrolizumab in advanced\, relapsed and refractory Hodgkin lymphoma. In advanced disease\, novel-agent combinations are improving outcomes\, while treatment selection should consider disease risk\, physiological fitness and expected toxicity rather than age alone. \nAccess and affordability remained central to the discussion. The speakers highlighted the need for locally relevant research\, including collaborative studies of lower-dose checkpoint inhibition\, alongside stronger tumour boards\, shared pathology expertise\, registries and tissue banking. Across the session\, the message was clear: Hodgkin lymphoma care is moving toward greater individualization\, but better outcomes will also depend on stronger diagnostic and research systems. \nKey Takeaways \n\nA negative interim PET does not completely exclude later treatment failure.\nTissue diagnosis remains essential when lymphoma is suspected or disease behaviour changes.\nNovel agents are expanding options in advanced\, relapsed and refractory Hodgkin lymphoma.\nTreatment intensity should reflect disease risk\, physiological fitness and toxicity\, not age alone.\nAccess challenges strengthen the case for locally relevant research and stronger collaborative lymphoma systems.
URL:https://kesho-kenya.org/event/advancing-hodgkin-lymphoma-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/09/WhatsApp-Image-2026-09-09-at-10.27.17-AM-e1788962859212.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260917T190000
DTEND;TZID=Africa/Nairobi:20260917T203000
DTSTAMP:20260924T171038Z
CREATED:20260917T130602Z
LAST-MODIFIED:20260924T171038Z
UID:41925-1789671600-1789677000@kesho-kenya.org
SUMMARY:Prostate cancer
DESCRIPTION:ADVANCES IN PROSTATE CANCER MANAGEMENT \n\nModerator: Prof Ngugi Mungai\nSpeakers: Prof Feng Wu\, Dr Palanki Satya Dattatreya\nDate: 17 September 2026\n\nThis session explored contemporary approaches to prostate cancer management\, bringing together advances in systemic therapy with emerging applications of high-intensity focused ultrasound (HIFU). \nDr Palanki Satya Dattatreya focused on the changing systemic treatment landscape across the prostate cancer continuum\, particularly metastatic castration-sensitive disease and non-metastatic castration-resistant prostate cancer. He emphasized the importance of moving beyond androgen deprivation therapy (ADT) alone for most patients and considering earlier treatment intensification with androgen receptor pathway-targeted therapies. \nA key theme was the need to define disease burden and presentation at the outset. Distinguishing between low- and high-volume disease\, and between de novo and recurrent metastatic disease\, can help guide treatment selection and provide important prognostic information. The session also reviewed the evidence supporting doublet and\, in selected fit patients\, triplet therapy\, while highlighting the importance of tailoring treatment to disease volume\, patient fitness and expected toxicity. \nThe presentation reviewed the role of next-generation androgen receptor pathway inhibition and highlighted PSA doubling time as an important marker in non-metastatic castration-resistant prostate cancer\, helping identify patients at higher risk of developing metastatic disease. \nDuring the discussion\, Dr Dattatreya reinforced that treatment decisions should not rely on chronological age alone. Physiological fitness\, performance status\, comorbidity\, expected toxicity and patient preference remain important when deciding how aggressively to intensify treatment. \nProf Feng Wu introduced HIFU as a non-invasive ablative technology that concentrates ultrasound energy within a defined target\, producing rapid local thermal injury and coagulative necrosis while avoiding surgical incisions. He reviewed its established and evolving applications in benign prostatic hyperplasia and presented early clinical experience in localized prostate cancer. \nHis presentation highlighted the precision required for HIFU\, including ultrasound or MRI guidance for treatment planning and monitoring. The discussion also addressed one of the challenges of focal treatment in prostate cancer: accurate tumour localisation. Some prostate cancers may not be clearly visible on MRI\, making biopsy information important when defining treatment targets and deciding between focal and whole-gland approaches. \nAcross the session\, a consistent message emerged: prostate cancer management is becoming increasingly individualized. Disease volume\, stage\, biology\, patient fitness\, treatment tolerance and access to newer technologies all influence the choice and sequencing of therapy. The expanding range of systemic and local treatment options makes multidisciplinary assessment increasingly important in determining the most appropriate pathway for each patient. \nKey Takeaways \n\nADT alone now has a limited role in many patients with advanced hormone-sensitive prostate cancer\, with treatment intensification increasingly central to contemporary management.\nDisease volume\, risk and whether metastatic disease is de novo or recurrent should be assessed early because these factors influence prognosis and treatment selection.\nNext-generation androgen receptor pathway therapies have expanded systemic treatment options across metastatic hormone-sensitive and non-metastatic castration-resistant disease.\nTreatment intensity should be individualized according to physiological fitness\, disease characteristics and expected toxicity rather than chronological age alone.\nHIFU is a non-invasive local treatment option for selected localized prostate cancers\, but accurate tumour localisation is critical.\nMultidisciplinary decision-making remains essential as treatment becomes more individualized.
URL:https://kesho-kenya.org/event/prostate-cancer-9/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/09/WhatsApp-Image-2026-09-17-at-3.58.00-PM-e1789650329636.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260924T190000
DTEND;TZID=Africa/Nairobi:20260924T203000
DTSTAMP:20260924T170220Z
CREATED:20260924T165755Z
LAST-MODIFIED:20260924T170220Z
UID:41931-1790276400-1790281800@kesho-kenya.org
SUMMARY:Cure in Chronic Myeloid Leukemia
DESCRIPTION:Beyond Control: Advancing Towards a Cure in Chronic Myeloid Leukemia \nDate & Time: 24th September 2026\, 7 PM – 8:30 PM EAT \nSpeakers: \n\nProf. Malkit Riyat — Associate Professor of Haematology and Consultant Haematologist\, Aga Khan University Hospital\nTopic: “The CML Care Pathway in Kenya: Optimising Treatment\, Molecular Monitoring and Access to Treatment-Free Remission”\nProf. Mhairi Copeland — Professor of Translational Haematology & Consultant Haematologist; Chair\, UK Blood Cancer Research Network; President\, Scottish Haematology Society\, University of Glasgow\nTopic: “Can CML Be Cured? Emerging Science and Global Progress Beyond Treatment-Free Remission”\nDr. Matilda Ong’ondi — Consultant Physician and Clinical Haemato-Oncologist at the Kenyatta National Hospital\n\n    	\n        Click to Register
URL:https://kesho-kenya.org/event/cure-in-chronic-myeloid-leukemia/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/09/WhatsApp-Image-2026-09-24-at-12.02.45-PM-e1790269179155.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20261119T080000
DTEND;TZID=Africa/Nairobi:20261121T170000
DTSTAMP:20260602T074510Z
CREATED:20260407T183641Z
LAST-MODIFIED:20260602T074510Z
UID:41566-1795075200-1795280400@kesho-kenya.org
SUMMARY:The 9th Kenya International Cancer Conference
DESCRIPTION:
URL:https://kesho-kenya.org/event/2026-kenya-international-cancer-conference/
CATEGORIES:Conferences,Webinar Recording Available
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-06-02-at-10.31.48-AM-e1780386294605.jpeg
END:VEVENT
END:VCALENDAR